CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Expression of programmed cell death protein 1 and programmed cell death ligand 1 in feline injection site fibrosarcomas.
Expression of programmed cell death protein 1 and programmed cell death ligand 1 in feline injection site fibrosarcomas.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
猫注射部位纤维肉瘤因其与注射部位的关联及侵袭性行为,在兽医肿瘤学中构成独特挑战。本研究探讨了免疫检查点程序性细胞死亡蛋白1和程序性细胞死亡配体1在该恶性肿瘤中的表达,旨在揭示其在肿瘤进展中的潜在意义。研究纳入了31例位于常见注射部位的猫纤维肉瘤存档诊断标本。通过免疫组织化学方法评估肿瘤细胞和TIL(肿瘤浸润淋巴细胞)中程序性细胞死亡蛋白1和程序性细胞死亡配体1的表达。分别在84%和81%的病例中观察到程序性细胞死亡蛋白1和程序性细胞死亡配体1的表达。在TIL(肿瘤浸润淋巴细胞)中,71%的病例观察到PD-1表达。
值得注意的是,较高的程序性细胞死亡蛋白1表达与肿瘤分级和炎症评分升高相关,提示可能与肿瘤侵袭性有关。同样,程序性细胞死亡配体1表达与肿瘤分级和炎症评分呈正相关。观察到的发现提示程序性细胞死亡蛋白1和程序性细胞死亡配体1在肿瘤微环境中的肿瘤进展和免疫反应中可能发挥作用。
此外,本研究有助于更深入地理解猫注射部位纤维肉瘤的发病机制,强调在制定针对这一棘手疾病的有效治疗策略时考虑免疫学视角的重要性。需要进一步研究以推进我们的知识并优化猫注射部位纤维肉瘤管理的治疗方法。
Feline injection site fibrosarcomas represent a unique challenge in veterinary oncology due to their association with injection sites and aggressive behaviour. The study explores the expression of immune checkpoints programmed cell death protein 1 and programmed cell death ligand 1 in the malignancy, aiming to unravel their potential significance in tumour progression. The study included 31, archival diagnostic specimens of feline fibrosarcomas, located in the common injection sites.
The programmed cell death protein 1 and programmed cell death ligand 1 expression in tumour cells and tumour infiltrating lymphocytes were assessed by immunohistochemical methods. Programmed cell death protein 1 and programmed cell death ligand 1 expression were observed in 84% and 81% of cases, respectively. In tumour infiltrating lymphocytes the PD-1 expression was observed in 71% of cases.
Notably, higher programmed cell death protein 1 expression correlated with tumour grade and heightened inflammation score, suggesting a potential association with tumour aggressiveness. Similarly, programmed cell death ligand 1 expression exhibited a positive correlation with tumour grade and inflammation score. The observed findings suggest a potential role for programmed cell death protein 1 and programmed cell death ligand 1 in tumour progression and immune response within the tumour microenvironment.
Moreover, this study contributes to a deeper understanding of feline injection site fibrosarcoma pathogenesis, emphasizing the importance of considering immunological perspectives in developing effective treatment strategies for this challenging condition.
Further investigations are warranted to advance our knowledge and refine therapeutic approaches for feline injection site fibrosarcoma management.
MEMBER ACCOUNT
登录成功会直接打开下一页。